Research in the UAE

Position of Cladribine Tablets in Managing RRMS

Published on Fri, 23 Apr 2021

Position of Cladribine Tablets in the Management of Relapsing-Remitting Multiple Sclerosis: An Expert Narrative Review From the United Arab Emirates

This expert narrative review outlines the practical use of cladribine tablets for managing highly active relapsing-remitting multiple sclerosis (RRMS). As an immune reconstitution therapy (IRT), cladribine tablets offer prolonged relapse-free periods with minimal monitoring. They are recommended for patients with highly active MS, poor adherence to continuous therapies, treatment-naïve cases with high disease activity, or those planning a family. The treatment has shown no adverse interaction with COVID-19 infections, and robust immune responses to vaccines have been observed, supporting safe COVID-19 vaccination during therapy.

Related research

Learn More
Switching from Fingolimod/Natalizumab to Cladribine Without Rebound
Fri, 1 Dec 2023

Switching from Fingolimod/Natalizumab to Cladribine Without Rebound

Learn More
Learn More
Adherence Challenges for High-Efficacy MS Therapies
Fri, 22 May 2020

Adherence Challenges for High-Efficacy MS Therapies

Learn More
Learn More
Living with MS: A Biopsychosocial Perspective
Tue, 17 Aug 2021

Living with MS: A Biopsychosocial Perspective